CD274 and ovarian cancer: Recently, a press release from Merck announced that the phase 3 KEYNOTE-B96/ENGOT-ov65 trial (NCT05116189) assessing pembrolizumab plus paclitaxel with or without bevacizumab reached the primary endpoint of PFS among patients with platinum-resistant ovarian cancer across the all-comer and PD-L1-positive populations.